ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0708

NFKB1 and NFKBIA: Relevant Players in the Pathogenesis of IgA Vasculitis?

Joao Carlos Batista-Liz1, Verónica Pulito-Cueto1, María Sebastián Mora-Gil1, Belén Sevilla-Pérez2, María Teresa Leonardo3, Norberto Ortego-Centeno4, Ana Peñalba3, Javier Narvaez5, luis martin penagos6, Emilio Rodrigo6, Lara Belmar-Vega6, Cristina Gomez-Fernandez7, Luis Caminal-Montero8, Paz Collado9, Miren Uriarte-Ecenarro10, Esther Vicente Rabaneda11, Esteban Rubio12, Manuel León Luque12, Juan María Blanco-Madrigal13, Eva Galindez-Agirregoikoa14, Santos Castañeda15, Miguel A Gonzalez-Gay16, Ricardo Blanco17 and Raquel López-Mejías1, 1Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, 2Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, 3Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Medicine Department, Universidad de Granada, Granada, Spain, 5Hospital Universitario de Bellvitge, Barcelona, Spain, 6Division of Nephrology, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-DIVAL, Santander, Spain, 7Division of Dermatology,Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, 8Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, 9Division of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, 10Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 11Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 12Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, 13Division of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, 14Basurto University Hospital, Bilbao, Spain, 15Hospital Universitario de la Princesa, Madrid, Spain, 16IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, 17Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Meeting: ACR Convergence 2023

Keywords: Biomarkers, genetics, Pediatric rheumatology, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Immunoglobulin A Vasculitis (IgAV) is a B-cell-mediated inflammatory disease. NF-kappa B (NF-kB) plays a key role in autoimmunity and inflammation1. In this regard, the development of B-cells is described as dependent on the activation of NF-kB2. In addition, NFKB1 (gene encoding NF-kB) is described as a shared risk locus for several immune-mediated diseases3. Specifically, NFKB1 is crucial in the pathogenesis of IgA nephropathy4,5, a disease that shares molecular mechanisms with IgAV. Accordingly, we aimed to determine whether NFKB1 and NFKBIA (gene encoding the NF-kB Inhibitor Alpha) represent novel genetic risk factors for IgAV.

Methods: 410 patients with IgAV, the largest series of Caucasian patients with IgAV ever assessed for genetic studies, and 764 healthy ethnically matched controls, were recruited for this study. Six tag single nucleotide polymorphisms (SNPs) within NFKB1 (rs77830930, rs1598856, rs7340881, rs4648055, rs4648090 and rs230547) and 7 NFKBIA tag SNPs (rs3138055, rs696, rs1022714, rs2233419, rs2233415, rs1050851 and rs1957106) were genotyped using TaqMan Probes. P-values were corrected with the FDR method for multiple testing.

Results: A statistically significant decrease of NFKB1 rs4648055 A allele was disclosed in patients with IgAV when compared to controls (p=0.013 OR=0.78 [0.64 – 0.95], Tables 1 and 2). Additionally, a statistically significant decrease in the NFKB1 GGCAGC haplotype was observed in IgAV patients compared to controls (p=0.007, Table 3). These results were not significant after FDR correction. No other statistically significant results were found in NFKB1 and NFKBIA genotype, allele, or haplotype frequencies between patients with IgAV and controls (Tables 1-3), nor when IgAV patients were stratified according to the age at disease onset or the presence/absence of gastrointestinal or renal manifestations (data not shown).

Conclusion: Our results suggest that NFKB1 and NFKBIA do not seem to be involved in the pathogenesis of IgAV.

References:[1] N Engl J Med 1997;336:1066-71; [2] Nat Immunol 2003;4:274-9; [3] Hum Mol Genet 2004;13:35-45; [4] Front Immunol 2019;10:815.; [5] Cell Biosci 2015;5:63.

This research was funded by European Union FEDER funds and “Fondo de Investigaciones Sanitarias” from “Instituto de Salud Carlos III” (ISCIII, Health Ministry, Spain), grant number PI18/00042 and PI21/00042. JCB-L is a recipient of a PFIS programme fellowship from the ISCIII, co-funded by the European Social Fund (“Investing in your future”), grant number FI22/00020. VP-C is supported by funds of “Fondo de Investigaciones Sanitarias” from ISCIII, grant number PI18/00042. MSM-G is supported by funds from IDIVAL, grant number TRANSVAL22/01. RL-M is a recipient of a Miguel Servet type II program fellowship from the ISCIII, co-funded by ESF (“Investing in your future”), grant number CPII21/00004.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: J. Batista-Liz: None; V. Pulito-Cueto: None; M. Sebastián Mora-Gil: None; B. Sevilla-Pérez: None; M. Teresa Leonardo: None; N. Ortego-Centeno: None; A. Peñalba: None; J. Narvaez: None; l. martin penagos: None; E. Rodrigo: None; L. Belmar-Vega: None; C. Gomez-Fernandez: None; L. Caminal-Montero: None; P. Collado: None; M. Uriarte-Ecenarro: None; E. Vicente Rabaneda: None; E. Rubio: None; M. León Luque: None; J. Blanco-Madrigal: None; E. Galindez-Agirregoikoa: None; S. Castañeda: None; M. Gonzalez-Gay: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Pfizer, 5, 6; R. Blanco: AbbVie, 5, 6, Amgen, 6, AstraZeneca, 2, BMS, 6, Eli Lilly, 6, Galapagos, 2, 6, Janssen, 2, 6, MSD, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 5, 6, Sanofi, 6; R. López-Mejías: None.

To cite this abstract in AMA style:

Batista-Liz J, Pulito-Cueto V, Sebastián Mora-Gil M, Sevilla-Pérez B, Teresa Leonardo M, Ortego-Centeno N, Peñalba A, Narvaez J, martin penagos l, Rodrigo E, Belmar-Vega L, Gomez-Fernandez C, Caminal-Montero L, Collado P, Uriarte-Ecenarro M, Vicente Rabaneda E, Rubio E, León Luque M, Blanco-Madrigal J, Galindez-Agirregoikoa E, Castañeda S, Gonzalez-Gay M, Blanco R, López-Mejías R. NFKB1 and NFKBIA: Relevant Players in the Pathogenesis of IgA Vasculitis? [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/nfkb1-and-nfkbia-relevant-players-in-the-pathogenesis-of-iga-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nfkb1-and-nfkbia-relevant-players-in-the-pathogenesis-of-iga-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology